Proxy adviser ISS backs ouster of Progenics CEO in activist battle

Emoji thumbs up
Activist investor Velan Capital scored a partial backing in its effort to oust Progenics' CEO and two directors. (Pixabay)

An activist investor is angling to oust Progenics' CEO after the drugmaker opted to sell instead of negotiating over board seats. Now, an influential proxy advisory firm has thrown its weight behind the CEO's removal and three of the challenger's nominees for Progenics' board. 

Institutional Shareholder Services (ISS) recommended the removal of CEO Mark Baker and the election of three board nominees from Velan Capital, which has waged a proxy fight against the drugmaker's "troubled track record."

The firm supported nominees Gérard Ber, David Mims and Eric Ende, a name familiar to those who follow biopharma proxy battles; for instance, he served on Genzyme's board ahead of that sale to Sanofi and worked with activist Carl Icahn during his challenges to Biogen leadership.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Velan applauded the ISS recommendation in a statement and urged shareholders to also elect two other nominees: Ann MacDougall and Heinz Mäusli.

"In our view, the addition of only three of our director nominees would represent insufficient change given the value destructive behavior of the current Board––behavior that ISS widely acknowledges throughout its report," Velan said.

RELATED: Progenics inked a merger to avoid negotiating a proxy war. One activist still wants to fight 

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.